Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Drug survival higher for ixekizumab vs secukinumab in moderate-to-severe plaque psoriasis

11 Jul 2019

More patients with moderate-to-severe plaque psoriasis discontinued treatment with secukinumab despite receiving significantly fewer biologics prior to initiating this drug as compared with those treated with ixekizumab, a recent study has shown.

Secukinumab and ixekizumab were administered to 368 and 62 patients, respectively. The corresponding proportion of bionaive patients was 40.7 percent and 12.9 percent. In addition, patients treated with ixekizumab had been given significantly more biologics in the past.

Of the bionaive patients, 23.5 percent in the secukinumab arm and none in the ixekizumab arm discontinued therapy over 12 months. Drug survival for bionaive and non-naïve patients was higher for ixekizumab than for secukinumab.

During the maximum follow-up of 3 years, drug survival among secukinumab users was lowest for those who have previously received two or more biologics, followed by those who received secukinumab as their second-ever biologic.

In this study, the authors used the DERMBIO registry to examine the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with moderate-to-severe psoriasis in Denmark. Danish patients receiving treatment with either drug based on standard in-label dosing were included in the analysis. Survival curves were presented using Kaplan-Meier plots.

The study was limited by its relatively small sample size and the short follow-up duration.

“Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).